Association of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma.
In our previous study, Human Signal Transduction in Cancer Gene Array was used in 12 fresh tumor samples to detect the gene expression profiles in the esophageal squamous cell carcinoma (ESCC) tissues matched adjacent non-cancerous samples. Among genes up-regulated at least twofold, β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 were found. So subsequently, the aim of this study was to investigate the prognosis and clinicopathologic roles of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 in ESCC tissue. The mRNA and protein expression levels of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 genes in 70 ESCC and adjacent non-cancerous paraffin-embedded samples were determined by Real-Time Quantitative PCR (RT-PCR) and immunohistochemical staining. The mRNA expression level of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 in ESCC was significantly higher than that in the adjacent non-cancerous tissues (0.0821 ± 0.0416 vs. 0.0185 ± 0.0201, P = 0.0000; 1.9934 ± 1.9888 vs. 0.8863 ± 0.665, P = 0.0184; 0.0298 ± 0.0215 vs. 0.0189 ± 0.0187, P = 0.0017; 2.098 ± 0.091 vs. 1.016 ± 0.078, P = 0.0000; 2.181 ± 2.158 vs. 0.931 ± 0.894, P = 0.0152; respectively), and the protein expression level of determined genes was also significantly higher than that in the adjacent non-cancerous tissues (0.2835 ± 0.0844 vs. 0.2352 ± 0.0670, P = 0.0003; 0.3830 ± 0.0947 vs. 0.2721 ± 0.1474, P = 0.0000; 0.2637 ± 0.0348 vs. 0.2042 ± 0.0180, P = 0.0000; 0.2058 ± 0.0316 vs. 0.1218 ± 0.0518, P = 0.0000; 0.2736 ± 0.0834 vs. 0.2251 ± 0.0571, P = 0.0001; respectively). Then, the overexpression of mRNA and protein levels of β-catenin, Wnt1 and Bmi-1 was aggressively associated with lymph node metastasis, advanced pathological stage, and prognosis of the patients with ESCC (P < 0.05). The up-expression of Hoxa9 mRNA and protein was also aggressively associated with lymph node metastasis and advanced pathological stage (P < 0.05); however, the overexpression of Hoxa9 protein was not associated with the prognosis (P > 0.05). Meanwhile, the hypo-expression of Smad4 mRNA was aggressively associated with advanced pathological stage and prognosis of the patients with ESCC (P < 0.05); however, the hypo-expression of Smad4 protein was neutral to the prognosis and lymph node metastasis (P > 0.05). β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 protein expression analysis showed that the positive outcomes of the combined detection of Wnt1 and β-catenin expression or Wnt1, β-catenin and Bmi-1 expression were significantly worse than those of a single target protein expression (P < 0.05). Meantime, the prognosis of the combined positive expression of Wnt1, β-catenin, and Bmi-1 was poorer than that in the combined positive expression of Wnt1 and β-catenin (P < 0.05). The prognosis of ESCC patients with the overexpression of Wnt1/β-catenin and Bmi-1 was relatively poor, and the level of Wnt1/β-catenin and Bmi-1 was conversely correlated with advanced pathological stage and lymph node metastasis. The expression level of Smad4 and Hoxa9 mRNA was also associated with the prognosis of the patients with ESCC, pathological stage, and lymph node metastasis; however, they might not be the independent prognostic factor.
Affiliated Nanjing First Hospital, Department of Oncology Surgery, Nanjing Medical University, Oncology Center of Nanjing Medical University, No 68 Changle Road, 210006 Nanjing, Jiangsu Province, China. cxf551101@sina.com
Jin
J
Lv
Xiu-Feng
XF
Cao
Lv
L
Ji
Bin
B
Zhu
Dong-dong
DD
Wang
Lei
L
Tao
Su-Qing
SQ
Li
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D020869:Gene Expression Profiling; D018398:Homeodomain Proteins / Q000096:biosynthesis; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000096:biosynthesis; D063150:Polycomb Repressive Complex 1; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis; D012333:RNA, Messenger / Q000032:analysis; D060888:Real-Time Polymerase Chain Reaction; D012097:Repressor Proteins / Q000096:biosynthesis; D051901:Smad4 Protein / Q000096:biosynthesis; D051155:Wnt1 Protein / Q000096:biosynthesis; D051176:beta Catenin / Q000096:biosynthesis
C069077:BMI1 protein, human; D014408:Biomarkers, Tumor; C495270:CTNNB1 protein, human; D018398:Homeodomain Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D012097:Repressor Proteins; C497796:SMAD4 protein, human; D051901:Smad4 Protein; C495247:WNT1 protein, human; D051155:Wnt1 Protein; D051176:beta Catenin; C097899:homeobox protein HOXA9; D063150:Polycomb Repressive Complex 1
Int J Cancer. 2001 Aug 15;93(4):516-25
11477555
Methods Mol Biol. 2007;361:63-91
17172707
Cancer. 2002 Aug 15;95(4):737-43
12209716
BMC Cancer. 2006 Sep 07;6:221
16959035
Stem Cells Dev. 2009 Jun;18(5):759-72
18800919
Neoplasma. 2008;55(3):165-76
18348648
Int J Cancer. 2005 Feb 10;113(4):515-24
15472907
Int J Cancer. 2009 Aug 1;125(3):556-64
19358268
Eur J Cancer. 1993;29A(6):887-93
8097920
Oncol Rep. 2007 Apr;17(4):753-60
17342311
Nat Rev Drug Discov. 2006 Dec;5(12):997-1014
17139285
Am J Clin Pathol. 2002 Mar;117(3):451-6
11888085
Int J Cancer. 1992 Jul 30;51(6):892-7
1379214
Biochem Biophys Res Commun. 2009 Mar 13;380(3):478-83
19284991
Cell Signal. 2009 Jan;21(1):22-33
18929644
Int J Cancer. 2005 Apr 10;114(3):436-41
15551325
Cancer Res. 2002 Jan 1;62(1):277-82
11782388
Methods Mol Biol. 2008;468:131-44
19099251
Cell Signal. 2008 Nov;20(11):2134-44
18762249
J Pathol. 1997 Jul;182(3):331-8
9349237
Oncology. 1997 Mar-Apr;54(2):158-65
9075789
Prostate. 2002 Feb 15;50(3):162-9
11813208
Oncogene. 2003 Sep 25;22(41):6462-8
14508527
J Biol Chem. 2008 Dec 19;283(51):35337-53
18952601
Pathol Res Pract. 2009;205(9):626-33
19324500
Dev Cell. 2008 Nov;15(5):773-80
19000841
Clin Cancer Res. 2007 Jul 15;13(14):4042-5
17634527
Nature. 1999 Jan 14;397(6715):164-8
9923679